根据《减少通货膨胀法》,美国处方药价格仍然大大高于高收入国家。 U.S. prescription drug prices under Inflation Reduction Act remain significantly higher than in high-income nations.
路透社的一项审查显示,美国政府根据《降低通货膨胀法》新谈判的处方药价格仍然大大高于其他高收入国家,其平均价格比其他高收入国家高出一倍多,有时甚至高出五倍多。 A Reuters review reveals that the U.S. government's newly negotiated prescription drug prices under the Inflation Reduction Act remain significantly higher—averaging more than double and sometimes five times—than prices in other high-income nations. Medirare首次披露这些价格表明,预计2026年将节省60亿美元。 Medicare's first disclosure of these prices indicates a projected savings of $6 billion in 2026. 美国愿意支付更多的 影响全球定价, 有利于制药公司。 The U.S.'s willingness to pay more influences global pricing, benefiting pharmaceutical companies.